Literature DB >> 26676757

Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease.

Stephen J Murphy1, Steven N Hart2, Geoffrey C Halling1, Sarah H Johnson1, James B Smadbeck1, Travis Drucker3, Joema Felipe Lima3, Fariborz Rakhshan Rohakhtar4, Faye R Harris1, Farhad Kosari1, Subbaya Subramanian5, Gloria M Petersen2, Timothy D Wiltshire6, Benjamin R Kipp6, Mark J Truty7, Robert R McWilliams8, Fergus J Couch9, George Vasmatzis10.   

Abstract

Many somatic mutations have been detected in pancreatic ductal adenocarcinoma (PDAC), leading to the identification of some key drivers of disease progression, but the involvement of large genomic rearrangements has often been overlooked. In this study, we performed mate pair sequencing (MPseq) on genomic DNA from 24 PDAC tumors, including 15 laser-captured microdissected PDAC and 9 patient-derived xenografts, to identify genome-wide rearrangements. Large genomic rearrangements with intragenic breakpoints altering key regulatory genes involved in PDAC progression were detected in all tumors. SMAD4, ZNF521, and FHIT were among the most frequently hit genes. Conversely, commonly reported genes with copy number gains, including MYC and GATA6, were frequently observed in the absence of direct intragenic breakpoints, suggesting a requirement for sustaining oncogenic function during PDAC progression. Integration of data from MPseq, exome sequencing, and transcriptome analysis of primary PDAC cases identified limited overlap in genes affected by both rearrangements and point mutations. However, significant overlap was observed in major PDAC-associated signaling pathways, with all PDAC exhibiting reduced SMAD4 expression, reduced SMAD-dependent TGFβ signaling, and increased WNT and Hedgehog signaling. The frequent loss of SMAD4 and FHIT due to genomic rearrangements strongly implicates these genes as key drivers of PDAC, thus highlighting the strengths of an integrated genomic and transcriptomic approach for identifying mechanisms underlying disease initiation and progression. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 26676757      PMCID: PMC4926317          DOI: 10.1158/0008-5472.CAN-15-2198

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition.

Authors:  Jie Cao; Xiao-Ping Chen; Wang-Lin Li; Jie Xia; Hong Du; Wei-Biao Tang; Hui Wang; Xi-Wen Chen; Huan-Qing Xiao; Yu-Yuan Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

2.  Effect of Wnt inhibitors in pancreatic cancer.

Authors:  Ilona Wall; Ingo G H Schmidt-Wolf
Journal:  Anticancer Res       Date:  2014-10       Impact factor: 2.480

3.  Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.

Authors:  Shinichi Yachida; Catherine M White; Yoshiki Naito; Yi Zhong; Jacqueline A Brosnan; Anne M Macgregor-Das; Richard A Morgan; Tyler Saunders; Daniel A Laheru; Joseph M Herman; Ralph H Hruban; Alison P Klein; Siân Jones; Victor Velculescu; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2012-09-18       Impact factor: 12.531

4.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

5.  Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer.

Authors:  Stephen J Murphy; Marie-Christine Aubry; Faye R Harris; Geoffrey C Halling; Sarah H Johnson; Simone Terra; Travis M Drucker; Michael K Asiedu; Benjamin R Kipp; Eunhee S Yi; Tobias Peikert; Ping Yang; George Vasmatzis; Dennis A Wigle
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

6.  Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.

Authors:  F Rödicker; T Stiewe; S Zimmermann; B M Pützer
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

7.  The role of zinc finger protein 521/early hematopoietic zinc finger protein in erythroid cell differentiation.

Authors:  Etsuko Matsubara; Ikuya Sakai; Jun Yamanouchi; Hiroshi Fujiwara; Yoshihiro Yakushijin; Takaaki Hato; Kazuhiro Shigemoto; Masaki Yasukawa
Journal:  J Biol Chem       Date:  2008-12-02       Impact factor: 5.157

Review 8.  Targeting Sonic Hedgehog: a new way to mow down pancreatic cancer?

Authors:  Keith A Cengel
Journal:  Cancer Biol Ther       Date:  2004-02-01       Impact factor: 4.742

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Smad4 haploinsufficiency: a matter of dosage.

Authors:  Paola Alberici; Claudia Gaspar; Patrick Franken; Marcin M Gorski; Ingrid de Vries; Rodney J Scott; Ari Ristimäki; Lauri A Aaltonen; Riccardo Fodde
Journal:  Pathogenetics       Date:  2008-11-03
View more
  15 in total

1.  SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFβ1 response and breast cancer metastasis.

Authors:  L Yu; Y Di; L Xin; Y Ren; X Liu; X Sun; W Zhang; Z Yao; J Yang
Journal:  Oncogene       Date:  2017-03-06       Impact factor: 9.867

2.  Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases.

Authors:  Matthew E Bechard; Anna E Word; Amanda V Tran; Xiaojing Liu; Jason W Locasale; Oliver G McDonald
Journal:  Oncogene       Date:  2018-05-30       Impact factor: 9.867

3.  Fhit down-regulation is an early event in pancreatic carcinogenesis.

Authors:  Matteo Fassan; Borislav Rusev; Vincenzo Corbo; Pierluigi Gasparini; Claudio Luchini; Caterina Vicentini; Andrea Mafficini; Salvatore Paiella; Roberto Salvia; Ivana Cataldo; Aldo Scarpa; Kay Huebner
Journal:  Virchows Arch       Date:  2017-03-13       Impact factor: 4.064

4.  Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type.

Authors:  Tommy Ivanics; John R Bergquist; Gang Liu; Michael P Kim; Yaan Kang; Matthew H Katz; Mayrim V Rios Perez; Ryan M Thomas; Jason B Fleming; Mark J Truty
Journal:  Lab Invest       Date:  2018-03-08       Impact factor: 5.662

5.  Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia.

Authors:  Tatsuo Hata; Masaya Suenaga; Luigi Marchionni; Anne Macgregor-Das; Jun Yu; Koji Shindo; Koji Tamura; Ralph H Hruban; Michael Goggins
Journal:  Am J Pathol       Date:  2018-04-22       Impact factor: 4.307

6.  An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma.

Authors:  Yoko Shimada; Takashi Kohno; Hideki Ueno; Yoshinori Ino; Hideyuki Hayashi; Takashi Nakaoku; Yasunari Sakamoto; Shunsuke Kondo; Chigusa Morizane; Kazuaki Shimada; Takuji Okusaka; Nobuyoshi Hiraoka
Journal:  Oncologist       Date:  2017-02-06

7.  Genomic rearrangements in sporadic lymphangioleiomyomatosis: an evolving genetic story.

Authors:  Stephen J Murphy; Simone B Terra; Faye R Harris; Aqsa Nasir; Jesse S Voss; James B Smadbeck; Sarah H Johnson; Vishnu Serla; Jay H Ryu; Eunhee S Yi; Benjamin R Kipp; George Vasmatzis; Eva M Carmona
Journal:  Mod Pathol       Date:  2017-06-23       Impact factor: 7.842

8.  Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

Authors:  Angela L McCleary-Wheeler; Ryan M Carr; Shanique R Palmer; Thomas C Smyrk; Jacob B Allred; Luciana L Almada; Ezequiel J Tolosa; Maria J Lamberti; David L Marks; Mitesh J Borad; Julian R Molina; Yingwei Qi; Wilma L Lingle; Axel Grothey; Henry C Pitot; Aminah Jatoi; Donald W Northfelt; Alan H Bryce; Robert R McWilliams; Scott H Okuno; Paul Haluska; George P Kim; Gerardo Colon-Otero; Val J Lowe; Matthew R Callstrom; Wen We Ma; Tanios Bekaii-Saab; Mien-Chie Hung; Charles Erlichman; Martin E Fernandez-Zapico
Journal:  Pancreatology       Date:  2019-11-21       Impact factor: 3.996

9.  Fhit loss-associated initiation and progression of neoplasia in vitro.

Authors:  Jenna R Karras; Morgan S Schrock; Bahadir Batar; Jie Zhang; Krista La Perle; Teresa Druck; Kay Huebner
Journal:  Cancer Sci       Date:  2016-10-03       Impact factor: 6.716

10.  Mut2Vec: distributed representation of cancerous mutations.

Authors:  Sunkyu Kim; Heewon Lee; Keonwoo Kim; Jaewoo Kang
Journal:  BMC Med Genomics       Date:  2018-04-20       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.